title: Influence of H. pylori infection and eradication on p53, c-erbB-2 and Ki-67 in gastric mucosa.
abstract: OBJECTIVE
  To evaluate the expression of antigens c-erbB-2, p53, and Ki-67 in gastric biopsy, bacteria density and urease activity in two groups of patients with chronic gastritis separated on the basis of the success or failure of H. pylori eradication.
  
  
  METHODS
  Sixty-five patients with chronic gastritis were split in two groups (n=45/20) related to response to the therapy. The gastric mucosa samples (Sydney system) were analyzed histologically in both groups of patients before and after standard therapy (for eradicated, E group after one cycle; for non-eradicated, NE group after three cycles) for H. pylori infection, urease activity, c-erbB-2, p53 and Ki-67 expression. Sera samples taken before and after treatment were also analyzed for specific antibody against H. pylori.
  
  
  RESULTS
  The eradication of H. pylori in patients of the E group was accompanied with significant lower colonization grades of bacteria, urease activity, proliferating rate, p53, and Ki-67 expression while c-erbB-2 expression was unchanged. In the NE group, all parameters were the same before and after therapy with exception of p53, which was slightly higher on both locations. Strong expression of c-erbB-2 in corpus of the NE group was determinate. Serum activity of specific antibodies against H. pylori was lower after the therapy in both groups of patients, but in the eradicated group this change was much stronger that in the non-eradicated.
  
  
  CONCLUSIONS
  Long persisting infection is related with higher colonization grades of bacteria, urease activity, p53, c-erbB-2 and Ki-67 expression. Changes of those markers are connected with duration of infection and location where these changes were obtained.
authors.affiliation: Research Institute PLIVA, Department of Pharmacology and Medicinal Safety, Zagreb, Croatia.
authors.forename: Karmen
authors.initials: K
authors.lastname: Brajsa
authors.forename: Zeljko
authors.initials: Z
authors.lastname: Ferencic
authors.forename: Miroslava
authors.initials: M
authors.lastname: Katicic
authors.forename: Senka
authors.initials: S
authors.lastname: Radosevic
authors.forename: Vladimir
authors.initials: V
authors.lastname: Presecki
authors.forename: Radan
authors.initials: R
authors.lastname: Spaventi
authors.forename: Marja
authors.initials: M
authors.lastname: Dominis
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000032:analysis; D049109:Cell Proliferation; D002908:Chronic Disease; D005260:Female; D005753:Gastric Mucosa / Q000737:chemistry / Q000378:metabolism / Q000382:microbiology; D005756:Gastritis / Q000188:drug therapy / Q000378:metabolism* / Q000382:microbiology*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000378:metabolism*; D016480:Helicobacter pylori / Q000201:enzymology / Q000302:isolation & purification; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000378:metabolism*; D015854:Up-Regulation; D014510:Urease / Q000032:analysis
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53; D014510:Urease